Inhalon Biopharma, Inc. (United States)

Homepage: inhalon.com

Alternate names: Inhalon Biopharma, Inhalon Biopharma, Inc.

ROR: 01wwy4233

OpenAlex ID: I4405267255

Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy

2020 · Carlos Cruz-Teran, Karthik Tiruthani, et al. · Advanced Drug Delivery Reviews · 90

Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19

2020 · Samuel K. Lai, Morgan D. McSweeney, et al. · Journal of Controlled Release · 29

Stable nebulization and muco‐trapping properties of regdanvimab/ IN ‐006 support its development as a potent, dose‐saving inhaled therapy for COVID ‐19

2022 · Morgan D. McSweeney, Ian Stewart, et al. · Bioengineering & Translational Medicine · 20

Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections

2024 · Morgan D. McSweeney, Sarhad Alnajjar, et al. · Advanced Science · 14

A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers

2025 · Thomas R. Moench, Lakshmi Botta, et al. · EBioMedicine · 13

Engineering a “muco‐trapping” ACE2 ‐immunoglobulin hybrid with picomolar affinity as an inhaled, pan‐variant immunotherapy for COVID ‐19

2024 · Karthik Tiruthani, Carlos Cruz‐Teran, et al. · Bioengineering & Translational Medicine · 7

Works count: 6

Citation count: 608